Published in Pediatr Nephrol on August 16, 2005
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3.19
Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol (2008) 2.64
Recurrent focal segmental glomerulosclerosis after kidney transplantation. Pediatr Nephrol (2015) 1.73
Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol (2011) 1.67
Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol (2013) 1.63
Rituximab in refractory nephrotic syndrome. Pediatr Nephrol (2009) 1.51
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int (2013) 1.33
Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2009) 1.21
Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol (2013) 1.18
Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant (2013) 1.13
Disease recurrence in paediatric renal transplantation. Pediatr Nephrol (2009) 1.10
Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol (2009) 1.01
Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol (2007) 1.00
Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol (2006) 1.00
Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol (2006) 0.98
The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transplant (2011) 0.97
Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol (2012) 0.92
Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor. World J Nephrol (2013) 0.92
Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant (2011) 0.90
Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children. Clin J Am Soc Nephrol (2015) 0.88
Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr (2007) 0.84
Nonimmunologic targets of immunosuppressive agents in podocytes. Kidney Res Clin Pract (2015) 0.84
Rituximab: is replacement of cyclophosphamide and calcineurin inhibitors in steroid-dependent nephrotic syndrome possible? Pediatr Nephrol (2007) 0.83
Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome? Pediatr Nephrol (2007) 0.82
Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis. Pediatr Nephrol (2012) 0.82
Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis. Pediatr Nephrol (2007) 0.81
Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation. Pediatr Nephrol (2009) 0.81
Should we consider MMF therapy after rituximab for nephrotic syndrome? Pediatr Nephrol (2011) 0.79
Monoclonal antibodies for podocytopathies: rationale and clinical responses. Nat Rev Nephrol (2009) 0.79
Rituximab for nephrotic syndrome in children. Clin Exp Nephrol (2016) 0.78
Update on the treatment of focal segmental glomerulosclerosis in renal transplantation. World J Transplant (2016) 0.78
Pediatric renal transplantation in a highly sensitised child-8 years on. Case Rep Transplant (2012) 0.78
Indications for use and safety of rituximab in childhood renal diseases. Pediatr Nephrol (2012) 0.77
Rituximab Treatment for Nephrotic Syndrome in Children. Curr Pediatr Rep (2015) 0.76
Nephrotic syndrome: what's new, what's hot? Korean J Pediatr (2015) 0.76
Treatment of steroid-resistant pediatric nephrotic syndrome. Korean J Pediatr (2011) 0.75
History of Nephrotic Syndrome and Evolution of its Treatment. Front Pediatr (2016) 0.75
Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open (2017) 0.75
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. Pharmaceuticals (Basel) (2016) 0.75
Long-term remission of nephrotic syndrome with etanercept for concomitant juvenile idiopathic arthritis. Pediatr Nephrol (2010) 0.75
Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med (1996) 4.41
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum (2005) 3.25
Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol (2003) 1.81
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
A glomerular permeability factor produced by human T cell hybridomas. Kidney Int (1991) 1.61
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation (2001) 1.53
Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr (2002) 1.47
Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet (1999) 1.46
Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol (2004) 1.37
Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol (1992) 1.34
Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med (1992) 1.24
Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol (2001) 1.24
Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol (2003) 1.09
High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis (2004) 1.06
Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol (1998) 0.99
Long-term evaluation of children with nephrotic syndrome and focal segmental glomerular sclerosis. Nephron (1983) 0.90
Nephrotic syndrome in a patient with intravascular lymphomatosis. Intern Med (2003) 0.84
Recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients: successful treatment with oral cyclophosphamide. Clin Transplant (1994) 0.81
Rituximab in the treatment of pediatric small bowel transplant patients with posttransplant lymphoproliferative disorder unresponsive to standard treatment. Transplant Proc (2002) 0.79
Recurrence of primary renal disease on kidney graft: a European pediatric experience. J Am Soc Nephrol (1992) 0.76
Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry. Br J Haematol (2002) 0.76
Effect of protein A immunoadsorption in nephrotic syndrome of various etiologies. J Am Soc Nephrol (1999) 0.75
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.5. Chronic graft dysfunction. Late recurrence of primary glomerulonephritides. Nephrol Dial Transplant (2002) 0.75
Prompt remission of post-renal transplant nephrotic syndrome with high-dose cyclosporine. Pediatr Nephrol (1994) 0.75
Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet (2010) 2.25
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Acute renal failure due to obstructive uric acid stones associated with acute gastroenteritis. Pediatr Nephrol (2009) 2.09
Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol (2012) 1.95
Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell (2005) 1.94
Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat (2007) 1.89
Genotype-phenotype correlations in alternating hemiplegia of childhood. Neurology (2014) 1.82
Variation in course of cavernous nerve with special reference to details of topographic relationships near prostatic apex: histologic study using male cadavers. Urology (2005) 1.80
Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol (2008) 1.67
Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol (2011) 1.67
A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis (2008) 1.63
Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int (2012) 1.61
Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol (2013) 1.60
Mortality rates for extremely low birth weight infants born in Japan in 2005. Pediatrics (2009) 1.59
A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet (2012) 1.58
A deep intronic mutation in the SLC12A3 gene leads to Gitelman syndrome. Pediatr Res (2009) 1.57
Identification of FOXP3-negative regulatory T-like (CD4(+)CD25(+)CD127(low)) cells in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Clin Immunol (2011) 1.57
Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol (2010) 1.57
Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr Nephrol (2014) 1.53
Effect of varicocelectomy on patients with unobstructive azoospermia and severe oligospermia. BJU Int (2007) 1.52
Rituximab in refractory nephrotic syndrome. Pediatr Nephrol (2009) 1.51
Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol (2005) 1.51
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol (2007) 1.49
Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol (2010) 1.49
Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol (2009) 1.49
Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol (2014) 1.46
Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old. Int Urol Nephrol (2012) 1.44
Long-term changes in renal function outcomes following radical cystectomy and urinary diversion. Int J Clin Oncol (2014) 1.44
Biopsy timing and Oxford classification variables in childhood/adolescent IgA nephropathy. Pediatr Nephrol (2014) 1.43
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol (2008) 1.41
Treatment strategies for Henoch-Schönlein purpura nephritis by histological and clinical severity. Pediatr Nephrol (2011) 1.39
Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature. Int J Urol (2011) 1.39
Renal biopsy criterion in children with asymptomatic constant isolated proteinuria. Nephrol Dial Transplant (2012) 1.38
Conventional versus microdissection testicular sperm extraction for nonobstructive azoospermia. J Urol (2002) 1.36
Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol (2011) 1.31
A nonsense mutation-created intraexonic splice site is active in the lymphocytes, but not in the skeletal muscle of a DMD patient. Hum Genet (2006) 1.30
Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther (2002) 1.30
Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol (2006) 1.24
Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull (2002) 1.23
Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res (2006) 1.22
Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis (2011) 1.20
Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer (2007) 1.19
Circadian clock genes directly regulate expression of the Na(+)/H(+) exchanger NHE3 in the kidney. Kidney Int (2005) 1.18
Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Clin Exp Nephrol (2013) 1.17
Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol (2011) 1.17
Two cases of ganglioneuroma. Urology (2006) 1.16
Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol (2011) 1.16
Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol (2008) 1.11
Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int (2002) 1.10
Japan Renal Biopsy Registry: the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol (2011) 1.08
Bilateral emphysematous pyelonephritis cured by antibiotics alone: a case and literature review. Jpn J Infect Dis (2009) 1.08
Analysis of NPHS1, NPHS2, ACTN4, and WT1 in Japanese patients with congenital nephrotic syndrome. Kidney Int (2005) 1.07
Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate (2007) 1.07
Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet (2006) 1.07
The pharmacological characteristics of molecular-based inherited salt-losing tubulopathies. J Clin Endocrinol Metab (2010) 1.07
A Japanese child with asymptomatic elevation of serum creatine kinase shows PTRF-CAVIN mutation matching with congenital generalized lipodystrophy type 4. Mol Genet Metab (2010) 1.06
Identification of specific autoantigens in Sjögren's syndrome by SEREX. Immunology (2005) 1.05
Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun (2011) 1.05
Genetic disorders of human congenital anomalies of the kidney and urinary tract (CAKUT). Pediatr Int (2003) 1.05
Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol (2008) 1.04
Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology (2008) 1.04
T cell-mediated control of Epstein-Barr virus infection in humanized mice. J Infect Dis (2009) 1.04
HNF1B alterations associated with congenital anomalies of the kidney and urinary tract. Pediatr Nephrol (2010) 1.03
Mechanisms of development and progression of cyanotic nephropathy. Pediatr Nephrol (2006) 1.03
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol (2009) 1.03
Low expression of human tubulin tyrosine ligase and suppressed tubulin tyrosination/detyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis. Int J Cancer (2004) 1.03
Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase. Prostate (2009) 1.03
Inhibition of amino acid-mTOR signaling by a leucine derivative induces G1 arrest in Jurkat cells. Biochem Biophys Res Commun (2003) 1.02
Epstein-Barr virus-associated B-cell lymphoma in a patient with DNA ligase IV (LIG4) syndrome. Am J Med Genet A (2007) 1.02
Quantification of lysophosphatidylcholines and phosphatidylcholines using liquid chromatography-tandem mass spectrometry in neonatal serum. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.02
Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int (2012) 1.02
Two-year outcome of the ISKDC regimen and frequent-relapsing risk in children with idiopathic nephrotic syndrome. Clin J Am Soc Nephrol (2013) 1.02
Genetic origins of the Ainu inferred from combined DNA analyses of maternal and paternal lineages. J Hum Genet (2004) 1.01
Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores. Urol Int (2007) 1.01
Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun (2004) 1.01
A novel mutation in the accessory DNA-binding domain of human steroidogenic factor 1 causes XY gonadal dysgenesis without adrenal insufficiency. Eur J Endocrinol (2007) 1.01
Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol (2007) 1.00
Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol (2009) 1.00
Molecular analysis of patients with type III Bartter syndrome: picking up large heterozygous deletions with semiquantitative PCR. Pediatr Res (2007) 1.00
Three major lineages of Asian Y chromosomes: implications for the peopling of east and southeast Asia. Hum Genet (2001) 0.99